IRIS/FUJIREBIO CO-DEVELOP 3GEMS HEMATOLOGY ANALYZER LINE.
Terms of the agreement call for Fujirebio to contribute $6 million toward the costs of the Joint Development Program, with an initial payment of $500,000 upon signing of the agreement and the balance to be paid in installments during the course of the development period based upon the achievement of certain milestones. These funds will be utilized to accelerate the 3GEMs Hematology development program, which leverages IRIS's proprietary image-based technology to automate the identification and characterization of blood cells, including an image-based expanded white blood cell differential, and is expected to significantly reduce the need for manual slide preparation and reviews.
"We are delighted with this expansion of our relationship with Fujirebio, which is currently our exclusive distributor in Japan for IRIS's series of Automated Urine Microscopy and Chemistry Analyzers," stated Cesar García, Chairman, president and CEO of IRIS International. "The extension into hematology of IRIS's core expertise in automated flow imaging technology and particle recognition represents a significant opportunity and we are pleased that Fujirebio has committed to partnering with us."
About Fujirebio Inc.
Headquartered in Tokyo, Japan, Fujirebio Inc., a company of Miraca Holdings, is a leading in vitro diagnostics (IVD) company specializing in the development, manufacturing and commercialization of IVD products. Fujirebio has achieved worldwide recognition for its achievements in immunodiagnostics, particularly for infectious diseases and cancer. The company provides IVD assay reagents and a series of fully automated analyzers, including its LUMIPULSE system based on chemiluminescent enzyme immunoassay, in Japan.
For more information visit www.fujirebio.co.jp/english/index.html.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,000 systems in more than 50 countries. The company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and body fluids. In addition, the company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the company's NADiA(R) ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease.
For more information, visit http://www.proiris.com or call 818/527-7000.
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 27, 2011|
|Previous Article:||NORGEN BIOTEK TO DEVELOP DIAGNOSTIC KITS FOR HOME USE.|
|Next Article:||INTERIM DATA SHOWS GOOD RESULTS FOR X-EXCITE VS. VIAGRA.|